Clotting Factors — CPB 0131 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0131 — its clotting factors coverage policy — effective February 19, 2026. Billing teams managing hemophilia A, hemophilia B, von Willebrand disease, and related coagulopathies need to review precertification requirements and product-specific criteria before submitting claims.

This update to CPB 0131 affects a wide range of HCPCS codes — from J7170 (emicizumab-kxwh) and J7214 (Altuviiio) to J7172 (marstacimab-hncq) and J7173 (concizumab-mtci), which are explicitly not covered. With 42 HCPCS codes and 35 CPT codes in scope, the financial exposure here is significant. Clotting factors are among the highest-cost specialty drugs in any payer's book. A missed precertification or wrong product selection generates a claim denial that is very hard to reverse.

---

Field	Detail
Payer	Aetna, a CVS Health company
Policy	Clotting Factors — CPB 0131
Policy Code	CPB 0131
Change Type	Modified
Effective Date	February 19, 2026
Impact Level	High
Specialties Affected	Hematology, Specialty Pharmacy, Home Infusion, Coagulation Disorders
Key Action	Verify product-specific criteria and precertify all clotting factor products through Aetna's Special Case Precertification Unit at (855) 888-9046 before dispensing

---

Aetna Clotting Factors Coverage Criteria and Medical Necessity Requirements 2026

The first thing to understand about this coverage policy is that precertification is not optional. Aetna requires precertification for all clotting factors — every product, every member, every applicable plan. Your team must call the Special Case Precertification Unit at (855) 888-9046. This is not a standard prior authorization line. Use the wrong number and you'll delay authorization or get routed incorrectly.

Medical necessity criteria under CPB 0131 are product-specific, not just indication-specific. That distinction matters. Billing Altuviiio (J7214) when the approved product is Kogenate FS (billed under J7190 or J7192) will trigger a denial even if the underlying diagnosis is identical. You need to match the approved product to the HCPCS code on the claim.

Factor VIII Products

Aetna covers Factor VIII products — including Advate, Adynovate, Afstyla, Alphanate, Altuviiio, Eloctate, Esperoct, Hemofil M, Humate-P, Koate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, and Xyntha — for hemophilia A when one of two conditions is met. For mild disease, the member must have had an insufficient response to desmopressin (J2597) or have a documented clinical reason for avoiding it. For moderate or severe disease, diagnosis alone is sufficient.

Jivi (J7208) has a narrower path. It requires that the member has previously received treatment with a Factor VIII product and is at least seven years old. Both conditions must be met. If a member is six years old — even with prior treatment — Jivi does not meet medical necessity criteria under this policy.

For von Willebrand disease, Alphanate, Humate-P (J7187), and Koate are covered products. The covered VWD types are 1, 2A, 2M, 2N (with desmopressin step-through), and 2B or type 3 (without the step-through requirement). Wilate (J7183) and Vonvendi (J7179) are also in scope under separate criteria.

Factor VIII Products for Acquired Conditions

Acquired hemophilia A is covered under a different product list than inherited hemophilia A. Aetna covers Advate, Alphanate, Hemofil M, Humate-P, Koate, Kogenate FS, Novoeight, Recombinate, and Xyntha for acquired hemophilia A. For acquired von Willebrand syndrome, the covered products narrow further to Alphanate and Humate-P only.

FEIBA (Anti-Inhibitor Coagulant Complex)

FEIBA (J7198) has its own medical necessity criteria. Aetna covers it for hemophilia A or B with inhibitors when the inhibitor titer is ≥5 Bethesda units per milliliter — or when the member has a history of a titer that high. It's also covered for acquired hemophilia A. The Bethesda unit threshold is a hard line. Document the titer result in the precertification request or expect a denial.

Continuation of Therapy

Reauthorization for any product listed under initial approval criteria requires documented benefit — specifically, reduced frequency or severity of bleeds. Build that clinical evidence into your reauthorization submissions now. Vague language like "patient tolerating therapy well" will not carry a reauth.

---

Aetna Clotting Factors Exclusions and Non-Covered Indications

Two HCPCS codes are explicitly not covered for the indications listed in CPB 0131:

#	Excluded Procedure Copy
1	J7172 — Marstacimab-hncq (0.5 mg)
2	J7173 — Concizumab-mtci (0.5 mg)

These are both subcutaneous monoclonal antibody therapies for hemophilia. Aetna classifies them as experimental, investigational, or unproven for the indications covered in this policy. If you're billing either of these codes against a hemophilia diagnosis expecting coverage under CPB 0131, stop. They're excluded.

Any indication not specifically listed in the initial approval criteria is also considered experimental or unproven. The policy does not have a catch-all "off-label but clinically supported" pathway. If the indication isn't named, it's not covered.

Note that J7170 (emicizumab-kxwh, Hemlibra) carries an important restriction: it is not covered in combination with Alhemo or Hympavzi. If a member is on any of those agents, the combination will generate a denial. Flag this in your prior authorization checklist.

---

Coverage Indications at a Glance

---

Aetna Clotting Factors Billing Guidelines and Action Items 2026

Clotting factor billing is high-stakes. These drugs can cost tens of thousands of dollars per infusion. One administrative miss wipes out significant reimbursement. Here's what to do now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Clotting Factors Under CPB 0131

HCPCS Codes Covered When Selection Criteria Are Met

HCPCS Codes Not Covered for Indications Listed in CPB 0131

Code	Description	Reason Copy
J7172	Injection, marstacimab-hncq, 0.5 mg	Experimental/investigational for listed indications
J7173	Injection, concizumab-mtci, 0.5 mg	Experimental/investigational for listed indications

Other HCPCS Codes Related to CPB 0131

CPT Codes Related to CPB 0131

Key ICD-10-CM Diagnosis Codes

Code	Description Copy
D66	Hereditary factor VIII deficiency (Hemophilia A)
D67	Hereditary factor IX deficiency (Hemophilia B)
B44.0	Invasive pulmonary aspergillosis (with hemoptysis)

The full policy references 210 ICD-10-CM codes. Review the complete code list at the CPB 0131 source policy before finalizing your coding.

---